PL
PTLA

Parkwood LLC’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Parkwood LLC’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,600
Closed -$298K – 549
2017
Q1 		$298K Sell
7,600
-16,400
-68% -$522K 0.04% 290
2016
Q4 		$539K Buy
24,000
+5,000
+26% +$97.7K 0.08% 170
2016
Q3 		$431K Buy
+19,000
New +$446K 0.06% 304

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Parkwood LLC's PTLA Position: Q2 2017 in Review

Parkwood LLC sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 7,600 shares — an estimated $298K sold.

Parkwood LLC first reported a position in PTLA in Q3 2016 and held it in 3 quarters. The position peaked at $539K in Q4 2016. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

  • Parkwood LLC reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Parkwood LLC sold 7,600 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $298K.
  • Parkwood LLC first reported a position in Portola Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • Parkwood LLC's Portola Pharmaceuticals, Inc. position peaked at $539K in Q4 2016.
  • 206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Parkwood LLC's 13F filing for Q2 2017, filed 25 Jul 2017.